ID   KP-N-RT-BM-1
AC   CVCL_1339
SY   KPNRTBM1; RT-BM-1; RT-BM 1; RTBM1; KP-N-RT-BM; KP-N-RTBM; RT-BM; KP-N-RT; Kyoto Pediatrics-Neuroblastoma-RT-Bone Marrow
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03470963
DR   BioSample; SAMN10987720
DR   cancercelllines; CVCL_1339
DR   Cell_Model_Passport; SIDM00557
DR   CGH-DB; 69-1
DR   CGH-DB; 9079-4
DR   ChEMBL-Cells; CHEMBL3308339
DR   ChEMBL-Targets; CHEMBL2366107
DR   Cosmic; 848926
DR   Cosmic; 924189
DR   Cosmic-CLP; 924189
DR   DepMap; ACH-000345
DR   GDSC; 924189
DR   GEO; GSM887239
DR   GEO; GSM888313
DR   GEO; GSM1670005
DR   IARC_TP53; 27697
DR   JCRB; IFO50432
DR   LiGeA; CCLE_682
DR   PharmacoDB; KPNRTBM1_786_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1339
DR   PubChem_Cell_line; CVCL_1339
DR   Wikidata; Q54900391
RX   CelloPub=CLPUB00582;
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=3731124;
RX   PubMed=11129446;
RX   PubMed=11501497;
RX   PubMed=12702577;
RX   PubMed=15892104;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23268333;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   HLA typing: A*24:02,31:01; B*35:03,56:01; C*01:02,03:03 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.43%; Native American=0.27%; East Asian, North=72.99%; East Asian, South=24.04%; South Asian=0%; European, North=0%; European, South=2.27% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP=924189; JCRB=IFO50432; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 10,12
ST   D18S51: 15,17
ST   D19S433: 13
ST   D21S11: 30,31.2
ST   D2S1338: 20
ST   D3S1358: 15,17
ST   D5S818: 10,13
ST   D7S820: 10,11
ST   D8S1179: 12,13
ST   FGA: 20,21
ST   Penta D: 9,12
ST   Penta E: 12,16
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 17,20
DI   NCIt; C4827; Adrenal gland neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9511 ! KP-N-RT-LN
SX   Female
AG   1Y2M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 35
//
RX   CelloPub=CLPUB00582;
RA   Sugimoto T., Kuroda H., Yagyu S., Gotoh T., Osone S., Tamura S.,
RA   Iehara T., Hosoi H.;
RT   "Cellular and molecular characteristics of established neuroblastoma
RT   cell lines.";
RL   J. Cancer Res. Therap. Oncol. 7:201.1-201.15(2019).
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999).
//
RX   PubMed=3731124;
RA   Sugimoto T., Sawada T., Matsumura T., Kemshead J.T., Ishii T.,
RA   Horii Y., Morioka H., Morita M., Reynolds C.P.;
RT   "Identical expression of cell surface membrane antigens on two parent
RT   and eighteen cloned cell lines derived from two different
RT   neuroblastoma metastases of the same patient.";
RL   Cancer Res. 46:4765-4769(1986).
//
RX   PubMed=11129446; DOI=10.1097/00019606-200012000-00007;
RA   Sugimoto T., Mine H., Horii Y., Takahashi K., Nagai R., Morishita R.,
RA   Komada M., Asada Y., Sawada T.;
RT   "Neuroblastoma cell lines showing smooth muscle cell phenotypes.";
RL   Diagn. Mol. Pathol. 9:221-228(2000).
//
RX   PubMed=11501497; DOI=10.2739/kurumemedj.48.159;
RA   Ueda K.;
RT   "Detection of the retinoic acid-regulated genes in a RTBM1
RT   neuroblastoma cell line using cDNA microarray.";
RL   Kurume Med. J. 48:159-164(2001).
//
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K.A., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23268333; DOI=10.1016/j.canlet.2012.12.011;
RA   Sugimoto T., Gotoh T., Yagyu S., Kuroda H., Iehara T., Hosoi H.,
RA   Ohta S., Ohira M., Nakagawara A.;
RT   "A MYCN-amplified cell line derived from a long-term event-free
RT   survivor among our sixteen established neuroblastoma cell lines.";
RL   Cancer Lett. 331:115-121(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//